Wei Li

Professor

Baylor College of Medicine

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Wei Li is a Professor at Baylor College of Medicine in the United States. His research focuses on anti-angiogenic therapies, particularly in relation to choroidal neovascularization and diabetic retinopathy. Recent publications include studies on targeting secretogranin III and the application of ligandomics in drug target profiling. He is also involved in developing novel gene therapies and methods for quantifying vascular leakage in retinal diseases.

Articles (14)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (2)

Midhat Abdulreda

Associate Professor of Surgery

University of Miami

UNITED STATES

View details

Keith A Webster

Adjunct Professor

Baylor College of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Wei Li

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Age-independent anti-angiogenic therapy for choroidal neovascularization by targeting secretogranin III

Feasibility of Ex Vivo Ligandomics

A method for rapid and reliable quantification of VEGF-cell binding activity

Optimal Humanized Scg3-Neutralizing Antibodies for Anti-Angiogenic Therapy of Diabetic Retinopathy

Suppression of matrigel-induced choroidal neovascularization by AAV delivery of a novel anti-Scg3 antibody

Anti-Scg3 Gene Therapy to Treat Choroidal Neovascularization in Mice

Secretogranin III Selectively Promotes Vascular Leakage in the Deep Vascular Plexus of Diabetic Retinopathy

Profiling disease-selective drug targets: From proteomics to ligandomics

Fluorescence Angiography with Dual Fluorescence for the Early Detection and Longitudinal Quantitation of Vascular Leakage in Retinopathy

Optimal efficacy and safety of humanized anti-scg3 antibody to alleviate oxygen-induced retinopathy

Selectively targeting disease-restricted secretogranin III to alleviate choroidal neovascularization

Comparative ligandomics implicates secretogranin III as a disease‐restricted angiogenic factor in laser‐induced choroidal neovascularization

Neurovascular abnormalities in retinopathy of prematurity and emerging therapies

Neurovascular regulation in diabetic retinopathy and emerging therapies

Collaborators (2)

Midhat Abdulreda

Keith A Webster

Make your next move.